Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lyell Immunopharma ( (LYEL) ) just unveiled an update.
On July 24, 2025, Lyell Immunopharma entered into a Securities Purchase Agreement to raise up to $100 million through a private placement with institutional and accredited investors. The initial closing, expected around July 25, 2025, will generate approximately $50 million, with the potential for an additional $50 million upon achieving specific clinical or corporate milestones within a year. The proceeds will fund pivotal-stage clinical trials of LYL314 and support general corporate purposes, with expectations to sustain operations into mid-2027. This financial move positions Lyell to advance its clinical trials and potentially submit a Biologics License Application in 2027 for LYL314 in treating large B-cell lymphoma.
The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s stock score reflects significant financial challenges, with zero revenue and operational losses being major concerns. However, promising trial data from their CAR T-cell therapy provides a positive outlook for potential future growth. Technical indicators are neutral, suggesting stability in the short term, while valuation remains a challenge due to lack of profitability.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. is a clinical-stage company focused on developing next-generation CAR T-cell therapies for treating hematologic malignancies and solid tumors. The company leverages advanced technologies to enhance CAR T cells’ durability and effectiveness, aiming to improve response rates and longevity in cancer treatment. Their lead product, LYL314, is designed to target CD19/CD20 in large B-cell lymphoma, and the company operates a manufacturing center capable of producing over 1,200 CAR T-cell doses.
Average Trading Volume: 133,444
Technical Sentiment Signal: Hold
Current Market Cap: $160.9M
For detailed information about LYEL stock, go to TipRanks’ Stock Analysis page.